化学工学による共性標的がん治療のためのアフィニティタンパク質薬
Xuelin Xia1, Wenhui Gao1, Xiaoyuan Yang1
1School of Chemistry and Chemical Engineering, Frontiers Science Center for Transformative Molecules, Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China.
Journal of the American Chemical Society
|May 30, 2025
まとめ
この研究は,腫瘍に不可逆的に結合する共性親和タンパク質薬を作る新しい方法を導入しています. このアプローチは腫瘍を標的とし 薬の有効性を向上させ 癌治療の有望な解決策となります
科学分野:
- 生物化学
- 化学生物学
- 腫瘍学
背景:
- アフィニティタンパク質は腫瘍をターゲットにするのに有望ですが,小さなサイズのため,迅速なクリアランスと腫瘍の蓄積に問題があります.
- 薬剤効果を薬剤動力学から切り離し,不可逆的な結合を作り出すことにより,共性標的化が解決策となる.
研究 の 目的:
- 結合的に標的型のタンパク質製薬を作るための化学改変戦略を開発する.
- アフィボディとモノボディのタンパク質薬を用いてこの戦略の有効性を実証する.
主な方法:
- 硫黄 (VI) フッ化物交換 (SuFEx) 化学ベースのマレイミド置換アリルフッ化物 (MFS) 結合剤による人工親和タンパク質.
- 共同結合,細胞吸収,腫瘍の保持,および腫瘍の成長抑制を試験したin vitroおよびマウスモデル.
主要な成果:
- MFSで改変されたアフィボディは,HER2への共性結合を72%以上,細胞吸収を185%以上in vitroを達成しました.
- 共性アフィボディはマウスで2. 01倍の腫瘍保持とほぼ完全な腫瘍増殖阻害を示した.
- EGFRを標的にするMFS-linker-armed monobodyにも同様の効果が認められた.
結論:
- 容易な化学改変戦略により,共性的に標的化された親和性タンパク質薬の作成が可能である.
- このアプローチは,タンパク質療法のための一般的なプラットフォームを提供し,様々な疾患における応用を加速させる可能性があります.
関連する概念動画
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Drug-Receptor Bonds
2.7K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
2.7K
Covalently Linked Protein Regulators
6.8K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.8K
Tumor Immunotherapy
489
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
489
Targets for Drug Action: Overview
6.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.1K


